TargetBeta
CACNB4
calcium voltage-gated channel auxiliary subunit beta 4 · also EJM4 · Membrane associated guanylate kinases
2 programs in company-led studies act on CACNB4, from 1 company: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Pregabalinrule | Viatris | phase 4 | 1493 running | CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8 | ChEMBL |
| Gabapentinrule | Viatris | phase 4 | 491 running | CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8 | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Diabetic Neuropathies, 2 programs
- Epilepsies, Partial, 2 programs
- Neuralgia, Postherpetic, 2 programs
- Fibromyalgia, 1 program
- Hot Flashes, 1 program
- Neuralgia, 1 program
- Sleep Initiation and Maintenance Disorders, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 31, 2027Gabapentin · Viatris · phase 4 · NCT07813026
- Jun 1, 2027Pregabalin · Viatris · phase 4 · NCT07712913
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.